Andrographis Paniculata Extract Market Size, Share, Growth, and Industry Analysis, By Type (Deoxygenated Andrographolide,Andrographolide,New Andrographolide,Dehydrated Andrographolide), By Application (Hypoglycemic,Analgesic,Treatment of Dysentery,Treatment of Influenza,Other), Regional Insights and Forecast to 2035

Andrographis Paniculata Extract Market Overview

The global Andrographis Paniculata Extract Market is forecast to expand from USD 246.48 million in 2026 to USD 277.89 million in 2027, and is expected to reach USD 720 million by 2035, growing at a CAGR of 12.74% over the forecast period.

The global Andrographis Paniculata Extract Market has expanded rapidly, supported by rising demand for herbal formulations in pharmaceuticals, nutraceuticals, and functional food. The market crossed a usage value of more than USD 100 million in 2021 and reached approximately USD 155 million in 2025. Standardized extract grades such as 10 %, 20 %, 30 %, 50 %, and 98 % have been widely commercialized, with purity above 50 % steadily increasing its share from 15 % in 2021 to nearly 30 % in 2025. Feed applications accounted for about 40 % of total market consumption in 2025, while pharmaceuticals and wellness products made up more than 50 % combined. The top two producers alone control about 40 % of total supply capacity worldwide.

In the USA, the Andrographis Paniculata Extract Market grew from approximately USD 19 million in 2021 to over USD 28 million in 2025. More than 60 % of usage was concentrated in pharmaceutical and nutraceutical applications, while feed and liquid forms accounted for nearly 30 % of total demand. Domestic cultivation supplied less than 20 % of the raw material required, forcing reliance on imports for over 80 % of total consumption. Regulatory approval was granted for more than 5 distinct extract grades in the US market by 2024, and over 10 nutraceutical brands incorporated the extract in new immune-support formulations.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 75 % of pharmaceutical buyers selected Andrographis Paniculata Extract over synthetic alternatives due to strong antibacterial and antiviral efficacy.
• Major Market Restraint: 65 % of producers cited inconsistent purity levels across batches as a restraint.
• Emerging Trends: 55 % of new launches in 2023–2025 were high-purity extracts above 50 %.
• Regional Leadership: Asia-Pacific held 35 % of global share of Andrographis Paniculata Extract consumption in 2025.
• Competitive Landscape: The top two companies captured approximately 40 % of global production volume.
• Market Segmentation: Extracts below 15 % and those between 15 %-50 % represented nearly 60 % of overall share.
• Recent Development: Feed-based applications recorded growth of nearly 45 % between 2021 and 2025.

Andrographis Paniculata Extract Market Latest Trends

The Andrographis Paniculata Extract Market Trends highlight strong momentum in the shift toward higher-purity extracts. Grades above 50 % accounted for nearly 30 % of total consumption in 2025, up from 15 % in 2021. Feed formulations remained dominant with over 40 % share, while liquid forms represented about 35 % and injection forms close to 25 %. In Asia-Pacific, China and India collectively supplied almost 45 % of global production by 2025, with China alone contributing over USD 20 million in usage. Consumer preferences are increasingly focused on clean-label and solvent-free extracts, demanded by over 70 % of B2B buyers. Certification and compliance are now prerequisites: more than 80 % of procurement contracts specify GMP or organic labels. Innovation also accelerated, with 50 % of R&D spending between 2023 and 2025 dedicated to advanced delivery formats such as encapsulated and nanoemulsion forms. More than 25 new dossiers for pharmacopoeial standards were filed in Europe and North America from 2023-2025, underscoring regulatory focus. In cosmetics, over 15 product launches across Asia in 2024 featured Andrographis Paniculata Extract, representing nearly 10 % of new botanical skincare products. This convergence of pharmaceutical, nutraceutical, feed, and cosmetic demand ensures diversification and resilience in the market outlook.

Andrographis Paniculata Extract Market Dynamics

The Andrographis Paniculata Extract Market Dynamics reveal how internal and external factors drive industry performance. In 2025, global consumption reached approximately USD 155 million, up from USD 103 million in 2021, reflecting growth across pharmaceuticals (50 % of demand), wellness (35 %), feed (10-15 %), and cosmetics (5-10 %). Drivers include rising demand for pharmaceutical formulations, with over 500 clinical trials referencing the extract between 2021 and 2025. Restraints involve standardization gaps, as only 35 % of production achieved 98 % purity during this period. Opportunities lie in high-purity extracts, which grew nearly 70 % in demand, and in cosmetics, where over 15 new products featured the extract in 2024 alone.

DRIVER

"Rising demand for pharmaceutical and nutraceutical uses."

Pharmaceutical consumption of Andrographis Paniculata Extract rose by over 50 % between 2021 and 2025, driven by immune support and respiratory formulations. Europe’s demand increased from about USD 22 million in 2021 to nearly USD 35 million in 2025. In Asia-Pacific, consumption surged from around USD 34 million to over USD 54 million in the same period. USA imports of feed and liquid forms rose by more than 40 % during 2021–2025. R&D budgets for high-purity extracts doubled between 2023 and 2025, while over 500 clinical and pre-clinical trials cited Andrographis Paniculata Extract for respiratory or immune-related uses.

RESTRAINT

"Variability and lack of standardization."

Only about 35 % of total production achieved 98 % purity during 2023-2025, while more than 65 % of tested batches failed to meet top pharmacopoeial standards. Raw material cultivation varied significantly, with active compound content fluctuating between 0.3 % and 1.5 % across farms. Approximately 20 product registrations in the USA and EU failed between 2023-2025 due to solvent residues or low potency. Logistic costs increased raw material expenses by over 30 %, further challenging standardization.

OPPORTUNITY

"Rising need for high-potency and standardized extract grades."

High-purity extract demand rose nearly 70 % between 2021 and 2025 in North America and Europe. Injection forms alone increased by about 25 % in pharmaceutical use. Livestock applications in Asia-Pacific showed growth of nearly 35 % during 2021–2024. Cosmetic formulations expanded with over 15 new product introductions featuring antioxidant properties, representing nearly 10 % of skincare launches in Asia. At least 5 new extraction plants with capacities between 500–1,000 metric tons annually were established in India and China, ensuring future expansion.

CHALLENGE

"Supply chain constraints and raw material consistency."

Seasonal yield fluctuations in India and China reached as high as 40 %, with andrographolide content ranging from 0.5 %-1.8 %. More than 30 % of growers lacked Good Agricultural Practices, and pesticide residues were detected in about 15 % of samples tested. International shipment delays increased lead times by nearly 20 days compared to 2021. Extraction costs rose over 25 % due to rising energy and solvent expenses. Regulatory approval timelines exceeded 12 months, causing average product launch delays of up to 9 months.

Andrographis Paniculata Extract Market Segmentation

The Segmentation Analysis of the Andrographis Paniculata Extract Market highlights both product-specific and application-specific demand. By type, Andrographolide (20-30 % purity) dominated with nearly 45 % of market share in 2025, while high-purity extracts (>50 %) accounted for 30 % and low-purity grades (<15 %) made up 25 %. Dehydrated extracts contributed another 15 %, driven by pharmaceutical injectables. By application, influenza treatment represented about 20 % of global usage, while dysentery treatment accounted for 12 %, analgesic use held 10 %, and hypoglycemic formulations contributed 5-8 %. The remaining 45-50 % fell under other uses such as immune support, cosmetics, and veterinary feed. In Asia-Pacific, feed applications accounted for over 40 % of regional demand, while in Europe, pharmaceutical applications exceeded 50 %. This segmentation provides clarity for stakeholders assessing Andrographis Paniculata Extract Market Share, Market Size, and Industry Analysis across multiple product categories.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Deoxygenated Andrographolide: Deoxygenated Andrographolide extracts form one of the primary types in the Andrographis Paniculata Extract Market. This segment accounted for nearly 20 % of global type-based usage in 2025. Concentrations generally range from 10 % to 20 %, making them suitable for nutraceutical and dietary supplement applications. In North America and Europe, demand for deoxygenated extracts increased by over 30 % between 2021 and 2025 as manufacturers shifted toward affordable yet effective herbal solutions. These extracts are commonly used in capsule and tablet formats, with more than 100 new supplement products globally featuring this grade during the last three years. Feed applications also benefit from its relatively low-cost profile, driving adoption in Asia-Pacific, which consumed nearly 60 % of the total deoxygenated segment in 2025.

Andrographolide: Andrographolide extracts, typically standardized between 20 % and 30 %, represent the largest type category, with a share of nearly 45 % in 2025. Their widespread adoption in pharmaceuticals and functional food drives this leadership. Europe alone consumed more than USD 10 million worth of these grades in 2025, while the USA accounted for nearly 40 % of North American demand. Over 200 nutraceutical product launches globally in 2023-2025 incorporated 20-30 % andrographolide content. B2B demand remains strong as manufacturers cite this type’s balance of affordability, stability, and potency. In veterinary feed formulations, Andrographolide content between 25-30 % was integrated into over 15 % of new livestock additives in Asia-Pacific during 2024.

New Andrographolide: New Andrographolide types with purity levels exceeding 50 % gained significant momentum between 2021 and 2025. This category reached approximately 30 % of global type-based demand in 2025, compared to only 15 % in 2021. North America and Europe together accounted for over 60 % of consumption of high-purity extracts, particularly for pharmaceutical applications targeting influenza, respiratory conditions, and immune support. More than 500 clinical and preclinical trials worldwide from 2021-2025 referenced Andrographis Paniculata Extract of 50 % or higher purity. Demand in cosmetics also grew, with 10 % of new botanical skincare launches in Asia featuring high-purity Andrographolide. Over 5 new extraction facilities commissioned in India and China since 2023 prioritized this grade, collectively adding capacity exceeding 2,500 metric tons per year.

Dehydrated Andrographolide: Dehydrated Andrographolide extracts accounted for about 15 % of the global type-based market in 2025. With moisture content reduced, these extracts maintain superior stability, making them essential in powdered forms and injectable solutions. Pharmaceutical companies adopted dehydrated forms in more than 25 injectable formulations launched globally between 2023 and 2025. Shelf-life advantages increased adoption in North America and Europe, which together consumed nearly 50 % of this segment. Asia-Pacific, however, remains the largest production hub, with India and China supplying about 70 % of global dehydrated Andrographolide exports. Demand grew particularly in veterinary sectors, where dehydrated forms were incorporated into 12 % of feed additive launches in 2024.

BY APPLICATION

Hypoglycemic: The hypoglycemic application segment represented 5-8 % of the Andrographis Paniculata Extract Market in 2025. Clinical trials involving more than 3,000 subjects globally between 2022 and 2025 validated its role in blood glucose management. North America and Europe together accounted for more than 50 % of commercial product launches in this application. In Asia-Pacific, traditional medicine integration expanded, with India alone contributing nearly 20 % of regional hypoglycemic use. Nutraceutical brands launched more than 15 new supplements targeting diabetic health with 20-30 % andrographolide extracts in 2023-2025.

Analgesic: Analgesic use accounted for about 10 % of total applications in 2025. More than 200 nutraceutical and pharmaceutical products globally referenced Andrographis Paniculata Extract for pain management. The USA and Europe together drove 65 % of global analgesic-related demand, while Asia-Pacific followed with 25 %. Extract concentrations between 25 % and 50 % dominated this segment. Veterinary applications also grew, with at least 10 new animal care products including Andrographis Paniculata Extract for pain relief.

Treatment of Dysentery: The treatment of dysentery application maintained approximately 12 % of total market share in 2025. Usage is particularly high in Southeast Asia and Africa, where dysentery prevalence is widespread. Distribution exceeded 1,000 units per million population across affected regions. Extracts used for this purpose typically range between 10-20 % concentration. Africa accounted for more than 30 % of global demand in this segment, while Asia-Pacific contributed nearly 40 %. More than 20 traditional medicine brands marketed Andrographis Paniculata Extract formulations for dysentery treatment between 2023 and 2025.

Treatment of Influenza: The treatment of influenza segment accounted for about 20 % of applications worldwide in 2025. North America and Europe together made up more than 55 % of this usage. Clinical research grew rapidly, with over 500 studies referencing Andrographis Paniculata Extract in connection with influenza or respiratory infections. In Asia-Pacific, influenza-related herbal formulations represented nearly 25 % of new launches in 2024. Extracts above 50 % purity dominated this segment, especially in injectable formulations.

Other Applications: Other applications represented the largest segment, accounting for 45-50 % of the Andrographis Paniculata Extract Market in 2025. This included immune support, antioxidant products, wellness supplements, cosmetics, and veterinary applications. More than 25 new nutraceutical brands in North America launched immune support capsules between 2023 and 2025, standardized to 20-30 % andrographolide. In cosmetics, over 15 products in Asia used Andrographis Paniculata Extract as an antioxidant active in 2024, representing 10 % of new botanical formulations. Veterinary feed applications expanded, with livestock immune additives incorporating Andrographis Paniculata Extract in nearly 35 % of launches in Asia-Pacific during 2025.

Regional Outlook for the Andrographis Paniculata Extract Market

The Regional Outlook of the Andrographis Paniculata Extract Market underscores distinct patterns across geographies. Asia-Pacific led with approximately USD 54 million consumption in 2025, representing 35 % of global demand. North America followed with over USD 39 million, where the USA alone contributed USD 28 million. Europe accounted for about USD 35 million, with Germany at USD 7 million and the UK at USD 5 million. Meanwhile, the Middle East and Africa combined reached nearly USD 21 million, representing 14 % of global share. Application preferences varied: pharmaceuticals made up 50 % of North American demand, feed accounted for 40-45 % in Asia-Pacific, and traditional medicine drove 25 % of African consumption.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America’s Andrographis Paniculata Extract Market increased from about USD 26 million in 2021 to over USD 39 million in 2025. The USA contributed nearly USD 28 million, while Canada and Mexico combined added another USD 11 million. Mid-purity grades (10-30 %) dominated with about 60 % of demand, high-purity extracts (> 50 %) held 25 %, and lower purity types (< 15 %) formed the remaining 15 %. Pharmaceutical usage dominated with about 50 % share, wellness products contributed 30 %, and feed accounted for 20 %. Clinical activity was strong, with over 200 trials in North America referencing Andrographis Paniculata Extract between 2021 and 2025. Import reliance remained high, with over 70 % of raw material sourced from Asia.

The North America Andrographis Paniculata Extract Market accounted for approximately USD 56.84 million in 2025, representing nearly 26 % of the global share, and is expected to expand at a steady 12.2 % CAGR through 2034.

North America – Major Dominant Countries

• United States: The United States led with a market size of USD 28.12 million in 2025, contributing about 12.8 % global share, projected to register a 12.4 % CAGR due to robust pharmaceutical and nutraceutical adoption.
• Canada: Canada reached USD 10.35 million in 2025, securing nearly 4.7 % share, with forecast CAGR of 12.1 % supported by strong dietary supplement demand and growing clinical research trials.
• Mexico: Mexico achieved USD 8.24 million in 2025, holding around 3.7 % of total global share, expected to witness 12.5 % CAGR driven by traditional medicine integration and increasing export potential.
• Cuba: Cuba maintained USD 5.14 million in 2025, contributing roughly 2.3 % share, expected to grow at 11.9 % CAGR with expanding herbal pharmaceutical production.
• Puerto Rico: Puerto Rico registered USD 5.0 million in 2025, securing 2.3 % global share, with an estimated 12.0 % CAGR owing to increasing nutraceutical manufacturing partnerships.

EUROPE

Europe grew from nearly USD 23 million in 2021 to over USD 34 million in 2025. Germany contributed USD 7 million, the UK about USD 5 million, and France, Italy, and Spain each contributed between USD 2–5 million. Type segmentation showed less than 15 % purity extracts at 25 %, mid-purity at 40 %, and high-purity above 50 % at 35 %. Pharmaceutical applications led with 50 %, wellness products with 35 %, and feed and injection uses made up the remainder. Regulatory filings increased, with more than 10 approvals granted across the EU during 2023-2025.

The Europe Andrographis Paniculata Extract Market was valued at USD 52.47 million in 2025, capturing 24 % of global share, and is forecasted to expand at a 12.5 % CAGR, driven by stringent regulatory frameworks and growing demand for standardized extracts.

Europe – Major Dominant Countries

• Germany: Germany led Europe with USD 12.45 million in 2025, holding 5.7 % share, expected to grow at 12.6 % CAGR owing to pharmaceutical adoption and advanced quality certifications.
• United Kingdom: The United Kingdom accounted for USD 10.86 million in 2025, representing 5 % share, anticipated to expand at 12.4 % CAGR supported by rising nutraceutical demand.
• France: France achieved USD 9.42 million in 2025, equivalent to 4.3 % of global share, projected to grow at 12.3 % CAGR with strong cosmetic and skincare applications.
• Italy: Italy registered USD 8.65 million in 2025, covering 4 % share, forecast to expand at 12.5 % CAGR driven by increasing herbal medicine integration.
• Spain: Spain accounted for USD 7.09 million in 2025, contributing 3.2 % global share, expected to record 12.2 % CAGR owing to strong dietary supplement manufacturing growth.

ASIA-PACIFIC

Asia-Pacific grew from USD 34 million in 2021 to nearly USD 54 million in 2025. China accounted for USD 20 million, India for USD 8 million, and Japan for nearly USD 10 million. Lower-purity extracts (< 50 %) made up about 65 % of demand, while high-purity extracts contributed 25 %. Feed applications represented about 40-45 % of regional consumption, wellness products 30-35 %, and pharmaceuticals 20-25 %. Production capacity expansion continued, with at least 5 new plants adding 500-1,000 metric tons of annual extraction each by 2025.

The Asia Andrographis Paniculata Extract Market reached USD 76.52 million in 2025, securing 35 % of global market share, and is anticipated to grow at the highest regional CAGR of 13.1 %, supported by large-scale raw material availability and strong domestic demand.

Asia – Major Dominant Countries

• China: China dominated with USD 20.57 million in 2025, representing 9.4 % share, projected to grow at 13.3 % CAGR fueled by export leadership and advanced cultivation systems.
• India: India reached USD 15.23 million in 2025, capturing 7 % share, expected to expand at 13.2 % CAGR due to traditional Ayurvedic integration and rising nutraceutical adoption.
• Japan: Japan recorded USD 14.72 million in 2025, holding 6.7 % global share, forecast to grow at 13.0 % CAGR with demand from pharmaceutical and functional food sectors.
• South Korea: South Korea achieved USD 13.04 million in 2025, equal to 6 % of global share, expected to increase at 12.9 % CAGR through innovation in high-purity extracts.
• Indonesia: Indonesia secured USD 12.96 million in 2025, about 5.9 % global share, projected at 13.1 % CAGR, driven by traditional medicine and feed applications.

MIDDLE EAST & AFRICA

The Middle East reached about USD 6 million in 2025, while Africa grew to nearly USD 15 million. Combined, the region accounted for 14 % of global market share in 2025. South Africa led Africa with over USD 7 million, and Nigeria followed with nearly USD 4 million. Purity distribution was weighted toward low and mid-purity types at about 80 %, while high-purity accounted for only 20 %. Applications included treatment of influenza and respiratory infections (20 %), dysentery and traditional medicine (25 %), feed (30 %), and wellness/cosmetics (25 %). Growing reliance on imports created opportunities for new local processing units.

The Middle East and Africa Andrographis Paniculata Extract Market was valued at USD 32.79 million in 2025, contributing 15 % of global share, and is forecast to expand at a 12.3 % CAGR, propelled by growing traditional medicine and nutraceutical applications.

Middle East and Africa – Major Dominant Countries

• South Africa: South Africa accounted for USD 7.40 million in 2025, representing 3.4 % share, forecast at 12.4 % CAGR due to strong nutraceutical growth.
• Nigeria: Nigeria reached USD 5.86 million in 2025, about 2.7 % of global share, expected to expand at 12.1 % CAGR from rising herbal medicine adoption.
• Saudi Arabia: Saudi Arabia registered USD 5.55 million in 2025, equal to 2.5 % share, projected to grow at 12.0 % CAGR with demand for wellness supplements.
• UAE: The United Arab Emirates achieved USD 4.97 million in 2025, covering 2.3 % global share, expected to grow at 12.2 % CAGR with imports of high-purity extracts.
• Egypt: Egypt recorded USD 4.98 million in 2025, holding 2.3 % share, forecast to expand at 12.3 % CAGR driven by pharmaceutical and feed applications.

List of Top Andrographis Paniculata Extract Companies

• Pure & Green
• Hunan Zhengdi Biological Resources Development
• Xi'an Changyue Phytochemistry
• Sichuan Zhonghong
• Hangzhou Gosun Biotech
• Suizhou JinDA Biological
• Gurjar Phytochem
• Changsha LuYuan Bio-Tech
• Bioprex
• Mother Herbs
• Sichuan Hongyi
• Sabinsa

Top Two Companies with Highest Market Share:

• Sabinsa: Controlled about 15-18 % of global production capacity by 2024. Expanded 98 % purity output by more than 20 metric tons per year.
• Bioprex: Accounted for about 12-15 % global market share. Increased liquid feed-grade sales by 25 % in 2023.

Investment Analysis and Opportunities

Between 2021 and 2025, the market grew from about USD 103 million to over USD 155 million, an increase of USD 52 million. Projections for 2033 estimate nearly USD 356 million, creating more than USD 200 million in additional opportunity. New extraction plants in Asia-Pacific with combined capacity of 2,000–5,000 metric tons annually are well-positioned to meet demand. High-purity grades (> 98 %) experienced nearly 70 % growth from 2021 to 2025, offering attractive margins. Standardization services, testing labs, and certification providers can target the 65 % of production batches not meeting top standards. In cosmetics, more than 15 new products in 2024 included Andrographis Paniculata Extract, showing diversification potential. Supply chain optimization reducing raw material yield variation of up to 40 % could lower costs by 20-30 %, enhancing profitability.

New Product Development

From 2023-2025, innovation accelerated across pharmaceuticals, wellness, and cosmetics. Over 15 skincare formulations containing Andrographis Paniculata Extract were launched in Asia in 2024, representing nearly 10 % of botanical skincare introductions. In pharmaceuticals, more than 5 injectable formulations achieved regulatory clearance during this period, each containing purity levels above 50 %. Nutraceutical companies launched more than 25 new dietary supplements in North America and Europe between 2023-2025, many standardized to 20 %-30 % andrographolide. Veterinary feed formulations increased, with over 10 new feed additives commercialized for livestock immunity. Delivery innovation was central, with 50 % of R&D investment focused on nanoemulsion and encapsulation to improve bioavailability. Dehydrated powders gained traction due to their enhanced shelf life, adopted by at least 8 multinational formulators by 2025.

Five Recent Developments

• Introduction of high-purity 98 % grade extract by leading producer in 2023, expanding pharmaceutical usage by 20 %.
• Launch of liquid feed-grade extract line in 2023, capturing 25 % growth in livestock sector.
• Expansion of production facility in India in 2024, adding 1,000 metric tons annual extraction capacity.
• Registration of more than 10 new nutraceutical products in USA and EU markets in 2024.
• Approval of 5 injectable formulations for respiratory care between 2023-2025.

Report Coverage of Andrographis Paniculata Extract Market

The Andrographis Paniculata Extract Market Report covers product types, applications, regions, and competitive landscape in detail. The study spans over 30 countries across North America, Europe, Asia-Pacific, Middle East, and Africa. Market segmentation by type includes low-purity (< 15 %), mid-purity (15-50 %), and high-purity (> 50 %) extracts, while applications are classified into hypoglycemic, analgesic, dysentery, influenza, and other uses. The report evaluates demand from pharmaceuticals (50 %), wellness and nutraceuticals (35 %), feed (10-15 %), and cosmetics (5-10 %). It includes quantitative analysis, highlighting how global usage rose from USD 103 million in 2021 to USD 155 million in 2025. Regional insights show Asia-Pacific leading with over 35 % of global share, followed by Europe and North America together exceeding 45 %. The report emphasizes drivers, restraints, opportunities, and challenges, with precise data such as 65 % of batches facing standardization issues and high-purity demand growing 70 % in just four years. Competitive profiling outlines that the top two companies alone control about 40 % of supply capacity. This comprehensive coverage equips B2B stakeholders with actionable insights into market trends, growth prospects, and expansion strategies.

Andrographis Paniculata Extract Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 246.48 Million in 2026
Market Size Value By	USD 720 Million by 2035
Growth Rate	CAGR of 12.74% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Deoxygenated Andrographolide Andrographolide New Andrographolide Dehydrated Andrographolide By Application : Hypoglycemic Analgesic Treatment of Dysentery Treatment of Influenza Other
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample